Navigation Links
Qualia Clinical Services Chooses ALPHADAS(R) for Phase I Clinical Trials
Date:10/21/2008

arly and late phase clinical trials. A full service contract research organization, Qualia has state-of-the-art clinical operations in Omaha, Nebraska , Toronto, Canada and Kiev, Ukraine. More information about Qualia can be obtained through its website at http://www.qualiaclinical.com

Logos Technologies is a leading provider of world-class integrated clinical trial solutions to the world's pharmaceutical, biotechnology and clinical research organisations. ALPHADAS is a clinical study management and fully mobile early Phase proactive EDC system that has been designed for real time eSource data collection. The system provides time based data entry at the bedside, collection and integration of laboratory data, images and scans and Bar-coded labeling to track samples from draw to dispatch. Logos Technologies established and proven product ALPHADAS sets the standard in collecting early Phase clinical trial data. ALPHADAS is fully compliant with industry standards and guidelines including FDA 21 CFR Part 11. More information about Logos Technologies can be obtained through its website at http://www.logostechnologies.com

For more information contact Angela King, Logos Technologies Ltd, +44(0)8707-478900

http://www.logostechnologies.com, http://www.qualiaclinical.com


'/>"/>
SOURCE Logos Technologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
2. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
3. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
4. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
7. Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution
8. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
9. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
10. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
11. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
(Date:8/28/2014)... 28, 2014 Amgen (NASDAQ: AMGN ... Application (BLA) to the U.S. Food and Drug Administration ... high cholesterol. Evolocumab is an investigational fully human monoclonal ... a protein that reduces the liver,s ability to remove ... blood. 1 ­ The ...
(Date:8/28/2014)... , Aug. 28, 2014  Rx Safes, Inc., ... announced that it is waging a new war on ... national media campaign. More than 2,500 children ... time and these drugs are easily accessed from unsecured medicine ... drug dealers on the streets, Rx Safes will address ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Rx Safes, Inc. Announces New War On Drugs 2
... , SAN DIEGO, Sept. 9 Anadys Pharmaceuticals, Inc. ... in a Phase II trial of ANA598 in patients chronically infected ... over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, ... non-nucleoside polymerase inhibitor. , , "ANA598 has demonstrated ...
... , , HERNDON, Va., Sept. 8 ... that it will initiate a global, Phase 3, multi-center pivotal trial ... proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for ... , BHR will enroll approximately 1,200 patients with ...
Cached Medicine Technology:Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 2Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 3Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 4Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598 5BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2
(Date:8/28/2014)... Steven Reinberg HealthDay Reporter ... salt in the diet may worsen symptoms of multiple sclerosis ... factors affect MS, such as vitamin D, smoking and Epstein ... may be another environmental factor affecting MS patients," said lead ... Neurological Research in Buenos Aires. Multiple sclerosis is a ...
(Date:8/28/2014)... 28, 2014 ABC television stars will ... MDA Show of Strength Telethon airing Sunday, Aug. 31, ... help raise funds and awareness to help save and ... muscle disease. , Viewers tuning into the 2014 telethon ... appeals and introductions from some of the network’s leading ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Biotronic, a ... leading intraoperative neurophysiology monitoring ("IONM") company, today announced the ... position of Chief Executive Officer effective immediately. Mr. Gecsey ... President and CFO in 2013 and has been an ... , “Bill’s efforts and achievements since joining the company ...
(Date:8/28/2014)... 28, 2014 Allegheny Health ... a regional partnership designed to advance sports nutrition ... competitive young athletes, scholastic athletes and their families ... Body & Mind Initiative will offer a comprehensive ... physical and mental dynamics involved in pursuing athletic ...
(Date:8/28/2014)... 28, 2014 Valero Renewable Fuels Company, ... (NYSE: VLO), and the Ports of Indiana hosted Lt. ... today at a Port Appreciation and Welcome Celebration commemorating ... plant. , “The opening of Valero’s ethanol facility at ... economic development win for the State of Indiana,” Ellspermann ...
Breaking Medicine News(10 mins):Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3
... WASHINGTON, Nov. 8 Speaker Nancy Pelosi and Democratic leaders held ... Affordable Health Care for America Act. The bill passed by ... opening remarks: , "I and some of my colleagues just ... Obama, congratulating us on a great victory for the American people. ...
... ... Company’s Mississauga, Ontario facility. , ... Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and ... a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze ...
... does not mean the battle is won," said Dr. Charmaine ... of 240-194, the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment to prohibit abortion mandates and ... Americans United for Life Action President and CEO Dr. Charmaine ... for the pro-life Americans across this country who have flooded ...
... of H.R. 3961 to Secure the Stability of Medicare ... Rohack, M.D., President, American Medical Association. , (Logo: ... of the House health reform bill, which will help improve ... swift passage of H.R. 3961 to secure the stability of ...
... Care Reform Bill , Critical legislation would ... BALTIMORE, Nov. 7 SUMMARY: Tonight the ... reform legislation that would strengthen Medicare for seniors and ... Americans out of affordable health coverage. , The Affordable ...
... The American Medical Association (AMA) today awarded its 2009 Benjamin ... Kraff, M.D., an ophthalmologist from Chicago, IL. The award recognizes ... of duty to make an outstanding public service contribution to ... the opening session of the 2009 Interim Meeting of the ...
Cached Medicine News:Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
96 channel Parallel dispenser using Positive Air Displacement Technology...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... The Labcyte Echo 550 compound ... droplets down to 5 nL using ... on focused acoustic energy. Monitoring of ... fluids enables the Echo 550 to ...
Medicine Products: